Sort   by:  
 Page size 
UnknownThe spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states.
Not available
S-EPMC9349320 | biostudies-literature
UnknownB-cell maturation antigen-based therapies post-talquetamab in relapsed or refractory multiple myeloma.
Not available
S-EPMC11182413 | biostudies-literature
UnknownEpigenomic translocation of H3K4me3 broad domains over oncogenes following hijacking of super-enhancers.
Not available
S-EPMC9341503 | biostudies-literature
UnknownWeight loss and dysgeusia in relapsed/refractory multiple myeloma patients treated with talquetamab.
Not available
S-EPMC11327703 | biostudies-literature
UnknownGeographic and Racial Disparities in Access to Chimeric Antigen Receptor-T Cells and Bispecific Antibodies Trials for Multiple Myeloma.
Not available
S-EPMC9419017 | biostudies-literature
UnknownVariability of definition of high-risk multiple myeloma across phase III clinical trials.
Not available
S-EPMC10188470 | biostudies-literature
UnknownBone remineralization of lytic lesions in multiple myeloma - The Arkansas experience.
Not available
S-EPMC8627246 | biostudies-literature
UnknownLong-term outcomes after autologous stem cell transplantation for multiple myeloma.
Not available
S-EPMC6988393 | biostudies-literature
UnknownPeripheral blood immune cell profiling and response to BCMA CAR-T cell therapy in relapsed refractory multiple myeloma.
Not available
S-EPMC12775428 | biostudies-literature
UnknownMesenchymal stem cells gene signature in high-risk myeloma bone marrow linked to suppression of distinct IGFBP2-expressing small adipocytes.
Not available
S-EPMC6361704 | biostudies-literature
Sort   by:  
 Page size